A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

开始日期2030-01-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT07158489

/ Not yet recruiting临床2期IIT

Protocol SAKK 18/ 25 Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Progressing on Immune Checkpoint Inhibitors: A Multicenter, Single-arm, Open-label Phase II Trial (ORIGIN2)

This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.

开始日期2026-03-01

申办/合作机构-

NCT06998940

/ Not yet recruiting临床3期IIT

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

开始日期2026-01-06

申办/合作机构

SWOG

[+1]

100 项与盐酸吉西他滨相关的临床结果

登录后查看更多信息

100 项与盐酸吉西他滨相关的转化医学

登录后查看更多信息

100 项与盐酸吉西他滨相关的专利（医药）

登录后查看更多信息

15,771

项与盐酸吉西他滨相关的文献（医药）

2025-09-01·ENVIRONMENTAL POLLUTION

Validation of a large volume-solid phase extraction methodology for biotoxicity assessment of pharmaceuticals in aquatic organisms

Article

作者: Gómez-Canela, Cristian ; Moragrega-Knol, Emma ; Barata, Carlos ; Romero-Alfano, Irene

The growing scarcity of freshwater has intensified the need for alternative water sources, which often require advanced treatments to eliminate contaminants. Among emerging pollutants, pharmaceuticals have become a significant concern due to their persistence and potential impact, making their detection essential. However, analysing these contaminants is challenging due to the extremely low concentrations at which they are present. For chemical analysis, minimal or no sample enrichment is often necessary, while bioanalysis typically requires larger sample volumes and an enrichment factor to conduct comprehensive bioassays across various endpoints. Consequently, sample preconcentration techniques for large water volumes are necessary to improve the sensitivity of subsequent toxicological experiments. In this study, a novel large volume solid-phase extraction (LV-SPE) procedure was validated and evaluated for monitoring multiple pharmaceutical compounds in water samples, while maintaining the traditional solid-phase extraction (SPE) methodology using cartridges. This method proved effective extraction and preconcentration of significant amounts of water, with recoveries between 19 % and 109 % in spiked wastewaters (except for fluvoxamine, remdesivir, tamoxifen and tetracycline, with recoveries <10 %). Furthermore, the optimization of this approach covers an expansive chemical space, enabling the capture of a diverse range of pharmaceutical compounds and enhancing the validity of toxicological studies. Bioassays conducted with Daphnia magna juveniles and Danio rerio embryos validated the method's applicability regarding optimized exposure conditions, the absence of adverse effects from SPE blanks or solvent controls and sensitivity in detecting effects across field samples. Overall, the LV-SPE approach enhances sensitivity and reliability for evaluating pharmaceutical mixtures' risks under realistic conditions.

2025-09-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Integrated network pharmacology and RNA sequencing analysis to reveal the mechanisms of Qici Sanling decoction in the treatment of gemcitabine resistant bladder cancer

Article

作者: Wang, Wanhui ; You, Bosen ; Geng, Bo ; Zhao, Enyang ; Wang, Jinpeng ; Liu, Weiyang ; Li, Xuedong ; Zhang, Wei ; Li, Zhuolun ; Nan, Yunfeng

Bladder cancer (BCa) is the most prevalent cancer of the urinary system in adults; the prognosis is dismal for BCa treated with gemcitabine (GEM) owing to intrinsic or acquired chemoresistance. This study investigated the potential of Qici Sanling decoction (QCSL), an herbal Chinese medicine, to augment the efficacy of GEM in treating GEM-resistant BCa via network pharmacology and RNA sequencing. We screened 103 active components of QCSL and their 226 targets from the TCMSP database and identified 3985 targets of GEM-resistant BCa via transcriptome sequencing. On the basis of the 69 common targets, a proteinprotein interaction (PPI) network was constructed to identify the top 7 targets. Disease Ontology (DO), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were conducted to uncover key pathways. CCK-8 assays, Western blotting, flow cytometry, colony formation, and EdU assays were used to assess the apoptosis and proliferation of GEM-resistant T24 and J82 cells treated with QCSL. The BCa gene set was among the top enriched gene sets in the DO analysis; GO analysis revealed enrichment of 2020 terms linked to GEM resistance, and KEGG analysis revealed 161 enriched signalling pathways. Molecular docking indicated that PTGS2 has high affinity for targets of QCSL components. In vitro experiments demonstrated that cells treated with both QCSL and GEM had significantly reduced viability, increased levels of apoptosis, and decreased proliferative capacity. Thus, QCSL enhances the therapeutic effects of GEM in BCa by promoting cell apoptosis and inhibiting cell proliferation. These findings have significant clinical implications, highlighting a potential combined treatment strategy for GEM-resistant BCa to improve patient outcomes.

2025-09-01·BIOMATERIALS

Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer

Article

作者: Sil, Diptesh ; Gendelman, Howard E ; Kapoor, Ekta ; Panja, Sudipta ; Khan, Rubayat I ; Jogdeo, Chinmay M ; Kumari, Neha ; Singh, Amar B ; Ding, Ling ; Siddhanta, Kasturi ; Oupický, David

The intractable and devastating nature of pancreatic ductal adenocarcinoma (PDAC) necessitates an urgent need for novel therapies. This study presents the development of a novel polymer prodrug system for the combination treatment of PDAC, based on an optimized pharmacologically active anti-metastatic macromolecular carrier, PCQ, conjugated with gemcitabine (GEM). Structure-activity relationship evaluations showed that random PCQ copolymers exhibited superior anti-migratory activity compared to the gradient PCQ analogs. GEM was incorporated into the random PCQ copolymers using disulfide linker to prepare a reduction-responsive prodrug, PCQ(r)6-SS-GEM12. The resultant therapeutic system presents a pharmacologically active delivery strategy that targets both the proliferative and the metastatic phenotype in PDAC. The PCQ(r)6-SS-GEM12 prodrug demonstrated a selective release of GEM under the reductive tumor environment leading to a significant inhibition of tumor growth with pronounced anti-metastatic effect. Collectively, our data show that the combination of anti-metastatic PCQ and cytotoxic GEM-based reduction-responsive prodrug polymer offers an innovative strategy to treat PDAC.

1,023

项与盐酸吉西他滨相关的新闻（医药）

2025-09-04

·香港证券交易所

自願性公告 - 和黃醫藥將於2025年世界肺癌大會和中國臨床腫瘤學會2025年年會公佈數據

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司（於開曼群島註冊成立的有限公司）（股份代號：13）自願性公告和黃醫藥將於2025年世界肺癌大會和中國臨床腫瘤學會2025年年會公佈數據和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「HUTCHMED」）今日宣佈將於2025年9月6日至9日在西班牙巴塞羅那召開的2025年世界肺癌大會（WCLC），以及2025年9月10至14日在中國濟南召開的中國臨床腫瘤學會（「CSCO」）2025年年會上公佈和黃醫藥自主研發的化合物的數項研究的最新及更新後的數據。賽沃替尼用於治療非小細胞肺癌的SACHI研究、SAVANNAH研究以及一項IIIb期驗證性研究的最新分析結果將於 2025年世界肺癌大會公佈。賽沃替尼是一種強效、高選擇性的口服MET酪氨酸激酶抑制劑（「TKI」），由阿斯利康與和黃醫藥共同開發，並由阿斯利康商業化。2025年世界肺癌大會的報告詳情如下： |公司申辦的研究|Col2|Col3| |---|---|---| |SAVANNAH研究: EGFR突變MET過表達和/或擴增的非小細胞肺癌患者中生物標誌物一致性和獲得性耐藥 SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC|Christina Baik, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA|MA03.03 迷你口頭報告 | Mini Oral: New Advances in Circulating Biomarkers Room 06 2025年9月7日 (星期日) 下午3:15 - 4:30 歐洲中部夏令時間| |賽沃替尼治療既往接受過或未接受過免疫治療的MET外顯子14跳變晚期或轉移性非小細胞肺癌患者的療效與安全性 Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy|虞永峰，上海胸科醫院，中國上海|P3.12.48 海報展示 | Poster: Metastatic NSCLC ‒ Targeted Therapy 2025年9月9日 (星期二)| |第三代EGFR-TKI治療失敗後MET擴增的非小細胞肺癌一線治療持續時間: SACHI研究的洞見 Frontline Treatment Duration in MET-Amplified NSCLC After Third- Generation EGFR-TKI Failure: SACHI Study Insights|陳利娟，鄭州大學附屬腫瘤醫院，河南省腫瘤醫院，中國鄭州|P3.12.64 海報展示 | Poster: Metastatic NSCLC ‒ Targeted Therapy 2025年9月9日 (星期二)| |奧希替尼及賽沃替尼治療EGFR突變伴MET過表達和/或奧希替尼治療後進展的晚期非小細胞肺癌: SAVANNAH研究的患者報告結果 Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs|Silvia Novello, University of Turin, San Luigi Hospital, Turin, Italy|PT2.12.04 電子壁報 | ePoster: Metastatic NSCLC ‒ Targeted Therapy 2025年9月8日 (星期一)| HMPL-653（一種新型、選擇性、強效的CSF-1R抑制劑）在中國腱鞘巨細胞瘤患者中開展的首個人體I期臨床試驗數據將於2025年CSCO年會上首次公佈。 CSCO 2025年年會報告詳情如下： |研究者發起的研究|Col2|Col3| |---|---|---| |呋喹替尼聯合斯魯利單抗用于一線治療轉移性或不可切除的非透明細胞腎細胞癌: 一項單臂、多中心臨床試驗的最新療效和安全性結果 Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy and Safety from a Multicenter, Single-Arm Trial|黃吉煒/ 薛蔚|23258 口頭報告 | Oral Session 2025年9月11日 (星期四) 下午16:50 - 17:15 中國時間| |呋喹替尼加卡瑞利珠單抗聯合紫杉醇脂質體和奈達鉑作為晚期食道鱗狀細胞癌的一線治療: 一項單臂II期臨床試驗的數據更新 Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): updated data from a single-arm, phase II clinical trial|邱天竹/ 顧艷宏|23766 口頭報告 | Oral Session 2025年9月12日 (星期五) 中午11:20 - 12:00 中國時間| |呋喹替尼聯合化療作為轉移性結直腸癌的二線治療: 一項多中心、開放標籤、II期臨床試驗 Fruquintinib plus chemotherapy as second-line therapy in metastatic colorectal cancer: a multicenter, open-label, phase II clinical trial|陳永順|22084 壁報交流 | Poster Session| |呋喹替尼聯合特瑞普利單抗和短程放療用於局部晚期直腸癌新輔助治療的II 期臨床試驗: 一項II期臨床試驗的最新療效和安全性結果 Efficacy and Safety of Neoadjuvant Fruquintinib plus Toripalimab and Short-Course Radiotherapy (SCRT) for Locally Advanced Rectal Cancer: Updated Results from a Phase II Clinical Trial|李志平|21915 論文摘要 | Abstract| |呋喹替尼聯合化療作為晚期轉移性結直腸癌的一線治療: 利用傾向評分匹配比較前瞻性單臂隊列與回顧性觀察性隊列的療效 Fruquintinib combined with chemotherapy as first-line treatment for advanced metastatic colorectal cancer: a propensity score-matched comparison of efficacy between a prospective single-arm cohort and a retrospective observational cohort|周福祥|23550 論文摘要 | Abstract| |摘要標題|報告人/ 主要作者|報告詳情| |---|---|---| |呋喹替尼聯合PD-1抑制劑和西達本胺用於治療微衛星穩定型(MSS)轉移性結直腸癌的療效和安全性: 與真實世界貝伐珠單抗聯合抗 PD-1和西達本胺組的比較 Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide arm|苟苗苗|23591 論文摘要 | Abstract| |索凡替尼聯合吉西他濱和順鉑加度伐利尤單抗/帕博利珠單抗方案治療晚期膽管癌的II期臨床試驗 Phase ll Clinical Study of Surufatinib Combined with Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer|苟苗苗|23610 口頭報告 | Oral Session 2025年9月12日 (星期五) 下午16:53 - 16:59 中國時間| |索凡替尼聯合KN046和吉西他濱、白蛋白紫杉醇作為不可切除晚期胰腺癌一線治療的單臂、Ib/II期臨床研究 A single-arm, Phase Ib/II trial of surufatinib plus KN046 and gemcitabine and nab-paclitaxel as first-line treatment for unresectable advanced pancreatic cancer|王文權/ 劉亮|23783 口頭報告 | Oral Session 2025年9月11日 (星期四) 下午16:20 - 16:35 中國時間| |索凡替尼聯合動脈栓塞術對比索凡替尼單藥用於治療伴肝轉移的神經內分泌瘤的最新結果: 一項前瞻性、隨機、對照研究 Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trial|曹丹|22652 壁報交流 | Poster Session| |索凡替尼治療一線標準化療失敗或安羅替尼治療失敗的軟組織肉瘤患者: 一項多中心、前瞻性、雙隊列、Ⅱ期臨床研究 Surufatinib in patients with soft tissue myeloma who have failed first- line standard chemotherapy or anlotinib: a multicenter, prospective, two-cohort, phase II clinical study|周宇紅/ 郭曦|P80 壁報交流 | Poster Session| |NASCA方案 (索凡替尼聯合卡瑞利珠單抗、白蛋白結合型紫杉醇和S-1) 治療伴肝轉移的晚期胰腺癌患者的療效和機制研究 Efficacy and Mechanistic Study of the NASCA Regimen (Surufatinib Combined with Camrelizumab, Nab-Paclitaxel, and S-1) in Advanced Pancreatic Cancer Patients with Liver Metastasis|戴廣海/ 賈茹|22309 論文摘要 | Abstract| |索凡替尼聯合賽帕利單抗和白蛋白結合型紫杉醇治療晚期三陰性乳癌的 II 期單臂研究: 數據更新 A Phase II, Single-Arm Study of Surufatinib Combined with Zimberelimab and Nab-Paclitaxel in Patients with Advanced Triple-Negative Breast Cancer: Data Update|王彩霞|23679 論文摘要 | Abstract| |索凡替尼聯合吉西他濱與順鉑和免疫檢查點抑制劑用于治療不可切除的局部晚期或轉移性肝內膽管癌的療效與安全性 Efficacy and safety of surufatinib combined with gemcitabine, cisplatin and immune checkpoint inhibitor for the treatment of unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma|石學濤/ 鐘敬濤|24133 論文摘要 | Abstract| |索凡替尼治療神經內分泌腫瘤患者的療效和安全性: 一項多中心回顧性研究 Efficacy and Safety of Surufatinib in Patients with Neuroendocrine Neoplasms: A Multicenter Retrospective Study|龍江|24294 論文摘要 | Abstract| 關於和黃醫藥和黃醫藥（納斯達克/倫敦證交所：HCM ；香港交易所：13）是一家處於商業化階段的創新型生物醫藥公司，致力於發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。自成立以來，和黃醫藥致力於將自主發現的候選藥物帶向全球患者，首三個藥物現已在中國上市，其中首個藥物亦於美國、歐洲和日本等全球各地獲批。欲了解更多詳情，請訪問：www.hutch-med.com或關注我們的LinkedIn專頁。前瞻性陳述本公告包含1995年《美國私人證券訴訟改革法案》「安全港」條款中定義的前瞻性陳述。這些前瞻性陳述反映了和黃醫藥目前對未來事件的預期，包括對呋喹替尼、索凡替尼、賽沃替尼和HMPL-653的治療潛力的預期，呋喹替尼、索凡替尼、賽沃替尼和HMPL-653的進一步臨床研究計劃，對呋喹替尼、索凡替尼、賽沃替尼和HMPL-653的研究是否能達到其主要或次要終點的預期，以及對此類研究完成時間和結果發佈的預期。此類風險和不確定性包括下列假設：入組率、滿足研究入選和排除標準的受試者的時間和可用性；臨床方案或監管要求變更；非預期不良事件或安全性問題；呋喹替尼、索凡替尼、賽沃替尼和HMPL-653（包括作為聯合療法）達到研究的主要或次要終點的療效；獲得不同司法管轄區的監管批准及獲得監管批准後獲得上市許可；呋喹替尼、索凡替尼、賽沃替尼和HMPL-653用於目標適應症的潛在市場，以及資金充足性等。此外，由於部分研究可能依賴於與其他藥物聯合使用，因此此類風險和不確定性包括有關這些治療藥物的安全性、療效、供應和監管批准的假設。當前和潛在投資者請勿過度依賴這些前瞻性陳述，這些陳述僅在截至本公告發佈當日有效。有關這些風險和其他風險的進一步討論，請查閱和黃醫藥向美國證券交易委員會、香港聯合交易所有限公司以及AIM提交的文件。無論是否出現新訊息、未來事件或情況或其他因素，和黃醫藥均不承擔更新或修訂本公告所含訊息的義務。醫療信息本公告所提到的産品可能並未在所有國家上市，或可能以不同的商標進行銷售，或用於不同的病症，或採用不同的劑量，或擁有不同的效力。本文中所包含的任何信息都不應被看作是任何處方藥的申請、推廣或廣告，包括那些正在研發的藥物。承董事會命非執行董事兼公司秘書施熙德香港，2025年9月5日於本公告日期，本公司之董事為：主席兼非執行董事：非執行董事：艾樂德博士施熙德女士楊凌女士執行董事：獨立非執行董事：蘇慰國博士莫樹錦教授（首席執行官兼首席科學官）（高級兼首席獨立非執行董事）鄭澤鋒先生言思雅醫生（代理首席執行官兼首席財務官）胡朝紅博士黃德偉先生

CSCO会议临床结果临床3期

2025-08-27

·ioncology

点击蓝字关注我们编者按晚期胆道癌（BTC）因起病隐匿、治疗手段有限，患者预后长期不佳，中位总生存期（OS）不足一年。尽管PD-1/PD-L1抑制剂联合化疗已成为一线标准，但客观缓解率（ORR）提升有限，亟需更高效的联合方案。既往有研究表明，PD-1/PD-L1与TIGIT双重抑制可能通过协同作用增强抗肿瘤效果。 2025年8月21日，复旦大学附属中山医院樊嘉院士、周俭教授、施国明教授团队在Signal Transduction and Targeted Therapy（STTT，IF=52.7）发表ZSAB-TOP研究结果。这项多中心、单臂、Ⅱ期临床试验（NCT050231109）首次评估了替雷利珠单抗（PD-1抑制剂）+欧司珀利单抗（TIGIT抑制剂）联合吉西他滨-顺铂（GemCis）方案治疗晚期BTC的疗效与安全性。符合条件的患者采用三药联合方案：每21天周期中，替雷利珠单抗（200 mg）和欧司珀利单抗（900 mg）于第1天给药，直至不可耐受毒性或疾病进展，同时吉西他滨（1000 mg/m²）和顺铂（25 mg/m²）于第1、8天给药，最多8个周期。主要终点为研究者评估的确认ORR。本次研究结果首次验证了PD-1/TIGIT双靶点阻断联合化疗的有效性，填补了国际空白，为无法手术的晚期BTC患者提供了新选择。尽管需Ⅲ期试验进一步验证，这一成果仍为一线治疗开辟了新方向，有望改写临床指南，彰显我国学者在肿瘤免疫联合治疗领域的创新实力。现本文对研究关键内容进行了整理，以飨读者。研究结果患者特征 2022年3月8日~2023年1月18日期间，研究共纳入45例患者并进入安全性分析集（SAS，图1）。患者中位年龄58.0岁，男性占55.6%。多数患者为TNM分期Ⅳ期（31例，68.9%），病灶起源于肝内（34例，75.6%），且60.0%存在转移性疾病。 44例（97.8%）患者完成TIGIT和PD-L1表达水平检测，具体分布为：TIGIT+/PD-L1+（18例，40.0%）、TIGIT+/PD-L1-（2例，4.4%）、TIGIT-/PD-L1+（13例，28.9%）、TIGIT-/PD-L1-（11例，24.4%）。图1. 研究概况疗效分析在疗效分析集（EAS，41例）中，研究者评估的确认ORR为51.2%（21/41例；95%CI：35.1~67.1），包含3例完全缓解（CR）和18例部分缓解（PR，图2a），达到统计学优效性标准（P=0.0003）。疾病控制率（DCR）为82.9%（34/41例；95%CI：67.9~92.8）,13例患者病情稳定（SD，包括2例未确认的PR）。在23例达到CR或PR（含2例未确认PR）的患者中，中位缓解持续时间（DoR）为6.4个月（95%CI：4.2~12.5）。EAS所有患者的治疗时间如图2b所示。3例（7.3%）患者经治疗后肿瘤显著缩小，符合手术指征并接受根治性手术。图2. 肿瘤反应。a.目标病灶大小相对于基线的最大百分比变化的瀑布图（n=38）。b.依据实体瘤疗效评价标准（RECIST）1.1版的治疗持续时间（n=41）。亚组分析 TIGIT+（12/18例，66.7%）或PD-L1+（17/28例，60.7%）患者的确认ORR高于TIGIT-（9/22例，40.9%）或PD-L1-（4/12例，33.3%）。为了进一步探索TIGIT和PD-L1状态的综合影响，根据这两种标志物对患者进行分层进：如图3所示，TIGIT+/PD-L1+亚组（16例）的确认ORR达75.0%（12例），显著高于其他亚组（TIGIT+/PD-L1-：0/2例；TIGIT-/PD-L1+：5/12例，41.7%；TIGIT-/PD-L1-：4/10例，40.0%）。所有3例完全缓解患者均属TIGIT+/PD-L1+亚组。确认的ORR在不同病理分型中，肝内胆管癌（ICC）为37.5%（12/32例），胆囊癌（GBC）为100%（8/8例），肝外胆管癌（ECC）为100%（1/1例）。图3. 疗效分析集中确认的ORR的亚组分析生存分析数据截止时（2024年7月19日），33例患者获得PFS。中位随访时间14.6个月，中位PFS为7.7个月（95%CI：6.0~9.4），12个月PFS率为26.4%（95%CI：13.5~41.3，图4a）。数据截止时，23例（56.1%）患者死亡。中位OS为17.4个月（95%CI：11.7~未达到），12个月OS率为65.9%（95%CI：49.3~78.2%，图4b）。按TIGIT/PD-L1状态进一步分层评估PFS和OS结果：TIGIT+患者的中位PFS为8.3个月，中位OS为NR；而TIGIT-患者中位PFS和OS则分别为7.4个月和12.9个月。对于PD-L1+与PD-L1-患者，中位 PFS分别为8.3个月和 7.0个月，中位OS分别为19.5个月和13.8 个月。当将TIGIT和PD-L1状态作为组合因素进行分析时：TIGIT+/PD-L1+亚组的中位PFS为9.4个月，OS未达到；而TIGIT+/PD-L1-亚组的中位PFS和OS分别为5.9个月和8.1个月，TIGIT-/PD-L1+为7.7个月和10.8个月，TIGIT-/PD-L1-为7.0个月和16.7个月。图4. 研究者评估的生存期Kaplan-Meier曲线。a. PFS的K-M 曲线；b. OS的K-M 曲线安全性分析所有患者（100.0%）均发生至少1次治疗相关不良事件（TRAE），其中97.8%（44例）出现治疗相关AEs。≥3级TRAE发生率为60.0%（27例），常见≥3级AEs为中性粒细胞减少（13例，28.9%）、白细胞减少（12例，26.7%）、血小板减少（8例，17.8%）和贫血（6例，13.3%）。45例患者中有11例 (24.4%) 出现严重不良事件 (SAE)，其中7例 (15.6%) 出现治疗相关SAE。TRAE导致7例患者（15.6%）停止化疗，3例患者（6.7%）停止免疫治疗。3 例患者（6.7%）出现导致死亡的TEAE，但均未被认为与治疗相关。免疫相关AEs发生率为42.2%（19例），常见为皮疹/皮炎（20.0%）、甲状腺功能减退（8.9%）和肌钙蛋白T升高（8.9%）。≥3级免疫相关AEs发生率为11.1%（5例），包括皮疹/皮炎（2例，4.4%）、肌酸激酶升高（1例，2.2%）、血小板减少（1例，2.2%）、自身免疫性心肌炎（1例，2.2%）和血栓形成（1例，2.2%）。研究分析与总结 ZSAB-TOP研究是首个评估在PD-1抑制剂与吉西他滨-顺铂（GemCis）标准联合方案基础上，添加TIGIT抑制剂治疗晚期BTC疗效与安全性的研究。结果显示，欧司珀利单抗、替雷利珠单抗与GemCis的三药联合方案，ORR达到51.2%，显著高于GemCis历史对照的25%（P=0.0003）。该方案的中位OS达17.4个月，提示肿瘤缓解可能带来长期生存获益。此外，双重免疫治疗联合GemCis的安全性可控，≥3级TRAEs发生率为60.0%。全球Ⅲ期KEYNOTE-966和TOPAZ-1试验已确立帕博利珠单抗或度伐利尤单抗联合GemCis作为新的一线标准，但其ORR仅较GemCis略有提升（分别为26.7%和29.0%），进一步凸显ZSAB-TOP研究中添加欧司珀利单抗后ORR改善的显著意义。此外，本研究OS达17.4个月，数值上长于度伐利尤单抗或帕博利珠单抗联合GemCis的12.7~12.8个月。但需注意，由于试验设计差异（如患者基线特征不同），此类跨试验比较需谨慎。具体而言，ZSAB-TOP研究纳入患者中位年龄更低、ECOG评分更优、转移性疾病比例更少，提示可能纳入更年轻、体能状态更好的低疾病负担人群。尽管如此，鼓舞人心的疗效和生存数据仍支持该方案在晚期BTC中的潜在价值，需进一步验证。除试验间差异外，疗效提升的可能机制之一在于免疫方案中新增了TIGIT抑制。首先，TIGIT抑制剂可直接调控免疫介导的抗肿瘤活性。其次，TIGIT对肿瘤微环境具有间接抑制作用。最后，TIGIT抑制剂与PD-1/PD-L1阻断剂具有协同作用。总体而言，TIGIT抑制剂可通过阻断TIGIT信号通路，增强NK/T细胞的抗肿瘤活性。ZSAB-TOP研究中，PFS数值上与KEYNOTE-966及TOPAZ-1试验相当，可能与BTC患者PFS评估的复杂性有关——该人群的疾病进展评估常依赖非影像学指标（如血清糖类抗原19-9水平、肝功能及胆道梗阻情况），因此基于RECIST 1.1标准的PFS可能无法完全反映真实疾病进展。鉴于PD-1/PD-L1与TIGIT在BTC浸润CD8+ T细胞中均高表达，双重免疫治疗在该疾病中值得探索。前期研究也发现，ICC患者中，TIGIT与PD-L1双阳性与更差的OS相关（复旦大学附属中山医院未发表数据），提示抗TIGIT与抗PD-L1联合治疗可能是ICC的潜在有效策略。本研究支持这一假设：TIGIT+或PD-L1+患者的确认ORR、PFS及OS均数值更高，尤以双阳性患者为著（ORR 75.0%）。值得注意的是，所有确认CR的患者均属TIGIT+/PD-L1+亚组。与既往报道一致，本研究中90%的TIGIT阳性患者同时为PD-L1阳性。总体而言，TIGIT与PD-L1共表达可能有助于识别BTC中更易从双抑制剂联合化疗中获益的人群，这还需进一步研究确认。目前，多项针对BTC的PD-1与TIGIT双重阻断Ⅲ期试验（NCT06467357、NCT06109779）正在进行，或将为该联合策略提供更多依据。晚期BTC研究常合并分析不同病理亚型，但各亚型的治疗反应与预后存在差异，需深入探讨。KEYNOTE-966与TOPAZ-1试验的亚组分析显示，免疫治疗联合化疗在ICC、ECC、GBC亚组中的疗效相当。而本研究中，GBC和ECC患者的肿瘤反应更优：所有GBC（8例）和ECC（1例）患者均达到客观缓解，而ICC患者的ORR为37.5%。有趣的是，GBC和ECC患者中TIGIT/PD-L1双阳性比例更高（GBC 75.0%、ECC 100%），而ICC患者中仅28.1%为双阳性。尽管受限于样本量，该结果提示GBC和ECC亚型中TIGIT与PD-L1更易共表达，且双重阻断可能在此类亚型中产生协同增效。未来需进一步探索各亚型中TIGIT/PD-L1的表达模式及双抑制剂联合化疗的疗效。安全性方面，替雷利珠单抗、欧司珀利单抗与GemCis的三药联合方案安全性可控，≥3级TRAEs发生率为60.0%，与TOPAZ-1（62.7%）和KEYNOTE-966（70.0%）试验相当。多数不良事件可通过暂停给药或对症支持治疗控制，未发生治疗相关死亡。此外，42.2%的患者出现免疫相关不良事件，与TIGIT和PD-L1抑制剂联合治疗的既往报道（21.9%~54.4%）相当。多数免疫相关不良事件为1~2级，无新发安全性信号。仅3例（6.7%）患者因TRAEs停用免疫治疗。总体而言，该方案在晚期BTC中的安全性可接受，未增加≥3级TRAEs或治疗中断的发生率。综上，替雷利珠单抗联合欧司珀利单抗及GemCis方案在晚期BTC中展现出令人鼓舞的抗肿瘤活性和生存获益，且安全性可控。该组合策略有望成为晚期BTC新的潜在一线治疗选择，未来仍需通过大规模Ⅲ期随机对照试验进行前瞻性验证，以指导临床实践。参考文献：[1] Shi, G., Huang, X., Ma, L. et al. First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study. Sig Transduct Target Ther 10, 260 (2025). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41392-025-02356-y （来源：肿瘤瞭望消化时讯）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床3期临床2期临床成功引进/卖出

2025-08-26

·ir.immuneering.com

Immuneering Announces Closing of $25 Million Private Placement

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The private placement was made to top-tier institutional and accredited investors, for total up front gross proceeds of approximately $25 million, before deducting fees and expenses. Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the company’s Class A common stock at a purchase price of $3.95 per share (or, for certain investors in lieu of Class A common stock, pre-funded warrants to purchase shares of Class A common stock), and (ii) accompanying purchase warrants to purchase an aggregate of 2,848,096 shares of Class A common stock, with each such warrant representing the right to purchase one share of the company’s Class A common stock at an exercise price of $5.50 per share. The pre-funded warrants were issued for a purchase price equating to $3.949 per pre-funded warrant share (which was the per share purchase price for the Class A common stock less the $0.001 per share unfunded exercise price for each pre-funded warrant). The investors were granted registration rights as part of the transaction. The purchase warrants are exercisable for a period of five years following the date on which the Class A common stock issued and issuable in the transaction are registered for resale. The offer and sale of the securities was made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Leerink Partners acted as a financial advisor to Immuneering for the private placement. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction. About Immuneering Corporation Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com. Forward-Looking Statements This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of atebimetinib, alone or in combination with other agents, including modified Gemcitabine/nab-paclitaxel (mGnP); and the expected amount and use of proceeds from this financing. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Media Contact: Gina Nugent Gina.nugent.external@immuneering.com Investor Contact: Laurence Watts 619-916-7620 laurence@newstreetir.com

临床2期

100 项与盐酸吉西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01155	盐酸吉西他滨	L01BC05	DB00441

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
局部晚期非小细胞肺癌	澳大利亚	Sandoz Pty Ltd.	2008-12-02
局部晚期胰腺腺癌	澳大利亚	Sandoz Pty Ltd.	2008-12-02
转移性非小细胞肺癌	澳大利亚	Sandoz Pty Ltd.	2008-12-02
转移性胰腺腺癌	澳大利亚	Sandoz Pty Ltd.	2008-12-02
复发性卵巢癌	澳大利亚	Sandoz Pty Ltd.	2008-12-02
尿路上皮癌	日本	Eli Lilly & Co.	2008-11-25
膀胱癌	巴西	Libbs Farmacêutica Ltda.	2008-05-26
胆道癌	日本	Eli Lilly & Co.	2001-08-31
淋巴瘤	日本	Eli Lilly & Co.	2001-08-31
卵巢癌	日本	Eli Lilly & Co.	2001-08-31
乳腺癌	美国	Eli Lilly & Co.	1996-05-15
转移性乳腺癌	美国	Eli Lilly & Co.	1996-05-15
非小细胞肺癌	美国	Eli Lilly & Co.	1996-05-15
胰腺腺癌	美国	Eli Lilly & Co.	1996-05-15
胰腺癌	美国	Eli Lilly & Co.	1996-05-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非肌层浸润性膀胱肿瘤	申请上市	美国	强生（中国）投资有限公司	2025-01-15
晚期胆道癌	临床3期	中国台湾	因华生技制药股份有限公司	2025-07-01
复发性膀胱癌	临床3期	美国	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	中国	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	日本	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	阿根廷	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	比利时	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	巴西	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	法国	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	德国	Janssen Research & Development LLC	2024-04-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03579771 (NEO-GAP, CTgov)	临床2期	肝内胆管癌	30	Nab-paclitaxel+Gemcitabine+cisplatin	淵襯鏇繭廠廠夢願築餘 = 顧淵餘鬱範網襯範顧觸築餘鑰網艱艱窪繭鏇鏇 (醖積築獵鏇製遞衊顧鑰, 壓衊憲鏇觸衊顧憲鑰遞 ~ 蓋艱鏇製廠憲鹹淵壓鹹) 更多	-	2025-08-15
NCT03739619 (CTgov)	临床1/2期	复发性经典霍奇金淋巴瘤 \| 难治性霍奇金淋巴瘤 \| 典型霍奇金淋巴瘤 ... 更多	3	Nivolumab+bendamustine+Gemcitabine	繭網窪襯網艱夢艱觸製 = 鏇襯簾窪簾積遞襯艱鬱餘壓鏇製淵遞鹽糧醖顧 (築窪範齋觸簾襯願繭壓, 憲艱鏇繭鬱願醖構獵廠 ~ 網鹹鹹鏇鬱窪構觸選鏇) 更多	-	2025-08-06
NCT03697564 (CTgov)	临床2期	胰腺腺癌 \| 胰腺癌	2	Cabiralizumab+Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]+Gemcitabine	願窪築鏇醖淵膚壓鑰選 = 簾艱簾積憲鹽繭簾鑰鏇範簾構繭鹹構繭築遞鑰 (簾鹽願鬱鹽衊憲網壓鏇, 鏇膚網繭壓餘獵齋糧簾 ~ 淵醖鹹窪膚鹽鬱鹹繭襯) 更多	-	2025-08-06
NCT04640623 (SunRISe-1, Pubmed \| J Clin Oncol)	临床2期	非肌层浸润性膀胱肿瘤	208	TAR-200 plus cetrelimab	夢襯淵顧糧願顧窪鹹襯(壓選夢艱蓋夢鹹窪觸淵) = 憲蓋顧顧廠壓簾夢選簾獵網鑰憲淵憲範醖鹽壓 (積構憲繭積築齋積築鑰, 72.6 ~ 89.8) 更多	积极	2025-07-30
				TAR-200 monotherapy	夢襯淵顧糧願顧窪鹹襯(壓選夢艱蓋夢鹹窪觸淵) = 壓顧衊築鑰築壓範鬱鹹獵網鑰憲淵憲範醖鹽壓 (積構憲繭積築齋積築鑰, 53.7 ~ 80.1) 更多
NCT03366415 (Pubmed \| JAMA Oncol) 人工标引	临床3期	鼻咽癌	420	Gemcitabine + cisplatin (SCRT group)	壓網衊鑰襯艱遞範鏇醖(鏇願鏇選膚醖衊窪構齋) = 鏇窪觸鹹淵鹹衊醖網鏇鹹願構窪網餘淵獵鹹鏇 (膚鑰築糧膚獵觸選鑰夢, 78.6 ~ 88.8)	非劣	2025-07-24
				GemcitabineGemcitabine + cisplatin (IC plus CCRT group)	壓網衊鑰襯艱遞範鏇醖(鏇願鏇選膚醖衊窪構齋) = 繭觸築淵範選壓糧憲衊鹹願構窪網餘淵獵鹹鏇 (膚鑰築糧膚獵觸選鑰夢, 74.0 ~ 85.0)
NCT02539537 (PRODIGE 29-UCGI 26 (NEOPAN), Pubmed \| J Clin Oncol)	临床3期	胰腺癌	-	FOLFIRINOX	淵製鑰餘遞網獵遞觸窪(繭願壓鏇艱鬱簾壓夢齋) = 艱醖衊艱網築簾齋廠鹹積範餘鹹簾衊鏇壓壓蓋 (積鑰築襯糧餘範築淵壓, 7.0 ~ 11.7) 更多	积极	2025-07-10
				Gemcitabine	淵製鑰餘遞網獵遞觸窪(繭願壓鏇艱鬱簾壓夢齋) = 艱窪範顧壓膚鹹鏇構積積範餘鹹簾衊鏇壓壓蓋 (積鑰築襯糧餘範築淵壓, 6.2 ~ 9.2) 更多
iLSTA (ESMO_GI2025 \| Company_Website) 人工标引	临床1/2期	晚期胰腺导管腺癌一线	30	GemcitabineGemcitabine + nab-paclitaxel + LSTA-1 + Durvalumab OR gemcitabine + nab-paclitaxel+placebo LSTA-1+ placebo durvalumab OR gemcitabinedurvalumab OR gemcitabine+ nab-paclitaxel+ activeo LSTA-1+placebo LSTA-1LSTA-1+ placebo durvalumab	鏇繭膚窪齋網觸獵糧鬱(鏇憲鏇齋獵餘蓋鹽襯簾) = 艱繭襯製窪製鬱築構選鏇醖築獵鑰廠廠範築製 (憲齋衊鬱製衊淵構繭膚 ) 更多	积极	2025-07-03
				gemcitabine+ nab-paclitaxel+ activeo LSTA-1+placebo LSTA-1+ placebo durvalumab (Cohort 2)	壓範網齋選鹹齋範網鹹(鹹範獵網艱夢襯網觸餘) = 願窪艱餘觸繭餘壓醖襯選鹹餘膚鏇窪觸選選壓 (淵鏇淵憲鑰鹹廠襯鬱構 )
NCT05497778 (COMBAT-PC, ESMO_GI2025) 人工标引	临床1期	胰腺癌	17	Lixumistat 400 malbumin-bound paclitaxelIV gemcitabine (Gem) (1000 mg/m²) + Lixumistatticle albumin-bound paclitaxel (NP) (125 mg/m²) and IV gemcitabine (Gem) (1000 mg/m²)	願鏇廠蓋壓遞範壓觸淵(獵選膚積觸積壓願獵窪) = 簾餘醖艱鏇鏇齋積膚製艱願繭積夢糧餘鏇網鬱 (構簾繭鹹鏇簾淵艱築願 ) 更多	积极	2025-07-03
				LixumistatLixumistat 800 mg QDalbumin-bound paclitaxelIV gemcitabine (Gem) (1000 mg/m²) + LixumistatLixumistat 800 mg QDalbumin-bound paclitaxel (NP) (125 mg/m²) and IV gemcitabine (Gem) (1000 mg/m²)	鹽獵範繭窪鬱獵網衊衊(憲鏇餘襯網窪壓鏇齋繭) = 廠顧鑰範鹹製鏇網遞淵積襯觸膚衊鏇廠簾觸艱 (鬱積簾憲構憲遞願鹹衊 )
NCT03260712 (ESMO_GI2025) 人工标引	临床2期	晚期胆道癌一线	50	Cisplatin/gemcitabine + Pembrolizumab	糧壓構顧獵遞艱網構窪(築醖餘鹹網憲獵遞衊壓) = 觸鬱淵選鬱範廠簾觸繭醖鏇選鏇艱鏇窪簾壓繭 (膚積獵醖顧鬱窪窪範鑰, 52 ~ 70) 更多	积极	2025-07-03
				CisplatinCisplatin/gemcitabine + Pembrolizumab (AJCC Stage II/III)	繭遞鹹艱鹹鬱蓋壓蓋膚(範鏇壓醖窪鬱顧願願糧) = 顧膚窪築築繭網鹹鏇鏇醖醖鹹範製蓋膚齋積鹹 (網鏇壓遞觸選鹽積淵鏇, 8.3 ~ NE) 更多
TriNetX Global Collaborative Network (ESMO_GI2025)	N/A	胰腺癌二线	1,520	Nanoliposomal irinotecan plus fluorouracil (NI)	積艱鬱襯構襯積遞齋廠(遞膚繭鬱夢鹽膚衊鹽襯) = 鬱鑰築鏇淵製獵選鏇壓廠齋夢願鬱憲觸窪繭鹽 (範窪鏇齋製顧鹹廠鑰衊 )	不佳	2025-07-03
				Fluoropyrimidine-based chemotherapy plus oxaliplatin (OF)	積艱鬱襯構襯積遞齋廠(遞膚繭鬱夢鹽膚衊鹽襯) = 鹽衊遞齋憲網遞餘鹹願廠齋夢願鬱憲觸窪繭鹽 (範窪鏇齋製顧鹹廠鑰衊 )